Histone Deacetylase Inhibitors: Current Status and Overview of Recent Clinical TrialsXUJUN MA; EZZELDIN, Hany H; DIASIO, Robert B et al.Drugs (Basel). 2009, Vol 69, Num 14, pp 1911-1934, issn 0012-6667, 24 p.Article

Genetic testing in cancer therapeuticsEZZELDIN, Hany H; DIASIO, Robert B.Clinical cancer research. 2006, Vol 12, Num 14, pp 4137-4141, issn 1078-0432, 5 p., 1Article

Methylation of the DPYD promoter : An alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patientsEZZELDIN, Hany H; LEE, Adam M; MATTISON, Lori K et al.Clinical cancer research. 2005, Vol 11, Num 24, pp 8699-8705, issn 1078-0432, 7 p., 1Article

Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolismTHOMAS, Holly R; EZZELDIN, Hany H; GUARCELLO, Vincenzo et al.Pharmacogenetics and genomics (Print). 2007, Vol 17, Num 11, pp 973-987, issn 1744-6872, 15 p.Article

Genetic regulation of ss-ureidopropionase and its possible implication in altered uracil catabolismTHOMAS, Holly R; EZZELDIN, Hany H; GUARCELLO, Vincenzo et al.Pharmacogenetics and genomics (Print). 2008, Vol 18, Num 1, pp 25-35, issn 1744-6872, 11 p.Article